Acasti Pharma Reports Fiscal Year 2022 Operational Results
June 21, 2022 08:00 ET
|
Acasti Pharma, Inc.
Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, June 21, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage,...
Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call
June 16, 2022 16:15 ET
|
Acasti Pharma, Inc.
LAVAL, Quebec, June 16, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern...
Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101
June 14, 2022 08:00 ET
|
Acasti Pharma, Inc.
LAVAL, Québec, June 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that three composition of matter patents for...
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints
May 18, 2022 07:30 ET
|
Acasti Pharma, Inc.
Bioavailability of IV GTX-104 compared favorably with the oral formulation of nimodipine, and no serious adverse events observed for GTX-104 Phase 3 remains on track to start before year-end ...
Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th
April 25, 2022 08:30 ET
|
Acasti Pharma, Inc.
LAVAL, Québec, April 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Prashant Kohli, Vice President of...
Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors
March 25, 2022 07:30 ET
|
Acasti Pharma, Inc.
LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announces that it has appointed Michael L. Derby to its Board of...
Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan
March 22, 2022 07:30 ET
|
Acasti Pharma, Inc.
LAVAL, Québec, March 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), announces the following patent notifications and awards relating...
Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th
March 09, 2022 08:30 ET
|
Acasti Pharma, Inc.
LAVAL, Quebec, March 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and Chief Executive...
Acasti Pharma Celebrates Rare Disease Day
February 28, 2022 08:30 ET
|
Acasti Pharma, Inc.
LAVAL, Québec, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today recognizes and celebrates Rare Disease Day (February 28),...
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022
February 14, 2022 07:00 ET
|
Acasti Pharma, Inc.
Provides updates on key milestones: GTX-104 PK study remains on track for results to be reported in the first half of calendar 2022; GTX-102 and GTX-101 progressing on schedule Conference call to be...